Bio-Techne Corp
NASDAQ:TECH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
61.66
84.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TECH stock under the Base Case scenario is 54.19 USD. Compared to the current market price of 71.28 USD, Bio-Techne Corp is Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bio-Techne Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TECH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Bio-Techne Corp
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate comp...
Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences.
For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.
Bio-Techne Corp. operates primarily in the life sciences and diagnostics sectors, providing a wide range of tools and reagents used in scientific research and clinical diagnostics. The company has three core business segments:
-
Protein Platforms: This segment focuses on providing high-quality proteins, antibodies, and other reagents for researchers in fields such as genomics, immunology, and cell biology. The products in this segment are essential for various applications, including drug discovery, vaccine development, and diagnostic tests. Bio-Techne's brands within this segment include R&D Systems and ProteinSimple.
-
Clinical Diagnostics: In this segment, Bio-Techne develops and markets a variety of in vitro diagnostic (IVD) products for clinical applications. This includes biomarkers and assays used for health monitoring, disease diagnosis, and therapy management. The products aim to enhance patient care and are utilized in hospitals, laboratories, and research institutions.
-
Cell & Gene Therapy: This segment encompasses tools and reagents used in the rapidly growing fields of cell and gene therapy. Bio-Techne provides products that support the development and manufacturing processes of these advanced therapeutic technologies, which have the potential to treat a range of genetic and acquired diseases.
Together, these segments position Bio-Techne as a key player in the biotechnology landscape, catering to both research and clinical markets with a robust suite of products and solutions.
Bio-Techne Corp operates in the life sciences and diagnostics industries, and it has several competitive advantages that differentiate it from its rivals:
-
Diverse Product Portfolio: Bio-Techne offers a wide range of products, which includes reagents, instruments, and consumables for life science research and clinical diagnostics. This diversity allows the company to cater to various sectors within the biotech and pharmaceutical industries.
-
Strong Focus on Innovation: The company invests significantly in research and development, leading to the continuous introduction of innovative products. This focus on innovation helps Bio-Techne stay ahead of its competitors and meet the evolving needs of its customers.
-
Proprietary Technologies: Bio-Techne has developed proprietary technologies that enhance the accuracy and efficiency of its products. These unique platforms and tools can create barriers for competitors and provide customers with distinctive products.
-
Strategic Acquisitions: The company has a history of acquiring complementary businesses that enhance its capabilities and product offerings. These strategic acquisitions enable Bio-Techne to expand its market reach and strengthen its competitive position.
-
Strong Brand Reputation: With a long-standing presence in the market, Bio-Techne has built a strong reputation for quality and reliability in its products. This brand trust can be a significant competitive advantage over newer or lesser-known rivals.
-
Global Presence: Bio-Techne operates in various international markets, which diversifies its revenue streams and reduces reliance on any single market. This global reach can also provide insights into regional trends and customer needs.
-
Customer Relationships: The company often collaborates with leading research institutions and pharmaceutical companies, which fosters deep customer relationships and loyalty. Strong partnerships can lead to repeat business and first access to new opportunities.
-
Expertise in Customized Solutions: Bio-Techne is known for its ability to provide customized solutions tailored to specific customer needs. This level of service can differentiate the company from competitors who may offer more generic products.
-
Regulatory Expertise: With its expertise in navigating complex regulatory environments, especially in the diagnostics space, Bio-Techne can better ensure compliance and expedite time-to-market for its products.
-
Commitment to Quality and Compliance: By maintaining high standards of quality and compliance throughout its operations, Bio-Techne enhances its credibility with customers and regulators, further solidifying its market position.
These competitive advantages enable Bio-Techne Corp to maintain a strong market presence and position itself favorably against its competition in the biotech and diagnostics landscape.
Bio-Techne Corp, like many companies in the biotechnology and life sciences sector, faces several risks and challenges that could impact its operations and growth in the near future. Here are some of the key considerations:
-
Regulatory Challenges:
- The biotechnology industry is heavily regulated. Changes in regulations or increased scrutiny from agencies like the FDA could complicate product development and approval processes.
-
Market Competition:
- The life sciences and biotech market is highly competitive, with numerous players offering similar products. Staying ahead of competitors in innovation and pricing strategies is crucial.
-
Technological Changes:
- Rapid advancements in technology require continuous investment in research and development to keep pace. Failing to innovate could lead to obsolescence.
-
Supply Chain Disruptions:
- Global supply chain issues, exacerbated by events like the COVID-19 pandemic, can impact the availability of raw materials and components essential for production.
-
Economic Factors:
- Economic downturns can lead to reduced funding for research and development, impacting sales for biotech companies. Tightening budgets in healthcare and research institutions may also affect sales.
-
Intellectual Property Risks:
- The biotechnology sector relies heavily on patents and intellectual property. Challenges such as patent expirations, litigation, or infringement issues can pose significant risks.
-
Public Perception and Ethical Concerns:
- Biotechnology often faces public scrutiny regarding ethical issues, particularly around genetic engineering and biotechnology applications. Negative public perception can influence sales and partnership opportunities.
-
Dependence on Key Customers:
- A significant portion of Bio-Techne's revenue may come from a limited number of customers. Losing a major customer could materially affect revenue.
-
Global Market Risks:
- As Bio-Techne expands internationally, it may face risks related to foreign market dynamics, including political instability, currency fluctuations, and changes in trade policies.
-
Talent Acquisition and Retention:
- The biotech sector requires highly specialized talent. Attracting and retaining skilled professionals can be challenging, especially in a competitive labor market.
-
Mergers and Acquisitions Risks:
- If Bio-Techne pursues growth through acquisitions, there are inherent risks, including integration challenges, cultural clashes, and overvaluation of acquired companies.
To manage these risks effectively, Bio-Techne will need to implement robust risk management strategies, remain agile in its operations, and maintain a strong focus on innovation and customer relationships.
Revenue & Expenses Breakdown
Bio-Techne Corp
Balance Sheet Decomposition
Bio-Techne Corp
Current Assets | 617.4m |
Cash & Short-Term Investments | 152.9m |
Receivables | 241.4m |
Other Current Assets | 223.2m |
Non-Current Assets | 2.1B |
PP&E | 342.4m |
Intangibles | 1.5B |
Other Non-Current Assets | 264.3m |
Current Liabilities | 159.4m |
Accounts Payable | 38m |
Accrued Liabilities | 87.6m |
Other Current Liabilities | 33.8m |
Non-Current Liabilities | 475.6m |
Long-Term Debt | 319m |
Other Non-Current Liabilities | 156.6m |
Earnings Waterfall
Bio-Techne Corp
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-389.3m
USD
|
Gross Profit
|
769.7m
USD
|
Operating Expenses
|
-521.3m
USD
|
Operating Income
|
248.5m
USD
|
Other Expenses
|
-80.4m
USD
|
Net Income
|
168.1m
USD
|
Free Cash Flow Analysis
Bio-Techne Corp
USD | |
Free Cash Flow | USD |
Bio-Techne began fiscal 2025 with a solid performance, reporting a 5% year-over-year revenue increase to $289.5 million. Adjusted EPS was $0.42, slightly up from $0.41 last year. The Diagnostics and Spatial Biology segment shone with a 14% jump in sales, while Protein Sciences saw a modest 1% growth. Strong demand in cell and gene therapy fueled optimism, with mid-single-digit growth expected in Q2. However, operating margins were impacted by product mix and reinstated compensation, leading to a guidance of 200-300 basis points lower for the first half. Overall, expectations remain intact, anticipating high single-digit exit rates by year-end.
What is Earnings Call?
TECH Profitability Score
Profitability Due Diligence
Bio-Techne Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Bio-Techne Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
TECH Solvency Score
Solvency Due Diligence
Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TECH Price Targets Summary
Bio-Techne Corp
According to Wall Street analysts, the average 1-year price target for TECH is 87.11 USD with a low forecast of 75.75 USD and a high forecast of 99.75 USD.
Dividends
Current shareholder yield for TECH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TECH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 2,600 full-time employees. The firm operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
Contact
IPO
Employees
Officers
The intrinsic value of one TECH stock under the Base Case scenario is 54.19 USD.
Compared to the current market price of 71.28 USD, Bio-Techne Corp is Overvalued by 24%.